ABOUT
As the Biotech and Pharma industries progress rapidly, the general expectation of better drugs with less or no toxic side effects and higher efficacy is a legitimate factor fueling innovation.
With naturally derived small molecules targeting multiple pathways, our drug candidates - OBX and OPX can change the paradigm of breast and prostate chemoprevention enhancing health span and lifespan.
With prior evidence of safety and efficacy in human use enabling consistent long term use and increased treatment adherence, OBX and OPX will lead to significant reduction in the risk for breast & prostate cancers compared to current standard of care.
Our unique approach is proactive and preventive, aiming to support and maintain cellular health, avoid and address cellular damage and carcinogenesis.
SCIENTIFIC APPROACH
We offer innovative solutions for chronic conditions with current unsatisfactory standard therapies, that affect a large percentage of both female and male demographic.
Fundamentally different from the current approach, OBX and OPX are delivering multiple active molecules that simultaneously and comprehensively target carcinogenic pathways at cellular level modulating the microenvironment of breast & prostate tissue.
One of the biggest challenges in breast and prostate cancer survival is tumor resistance & relapse following endocrine, hormone inhibition therapy.
Current chemotherapy protocols for breast and prostate combine 2 or 3 drugs in order to obtain better result than single targeted approach and delay the inevitable tumor mutation resulting in resistance to administered drugs and the need for additional & stronger drugs.
Today, in spite of huge progress in cancer care, over 50% of breast cancers are relapsing during a 10 up to 32 years time frame after primary diagnosis, and 20-30% of prostate cancers relapse after 5 years highlighting the need for on-going chemoprevention without side effects in order to block/inhibit carcinogenesis and enable life long cancer-free status.
According to Cancer research UK "1 in 2 people in the UK will get cancer in their lifetime" while in the US 1 in 2 women and 1 in 3 men will develop cancer in their lifetime.
Researchers at EMBL’s European Bioinformatics Institute (EMBL-EBI) and the Francis Crick Institute have discovered that Cancer mutations occur decades before diagnosis.
Our approach is acting early, in the absence of disease, or when patient is in remission, in order to disrupt and block carcinogenesis and protect cellular health.
We aim to help change these dreadful odds with safe, effective and affordable compositions in order to prolong health span and longevity.
PIPELINE
We are developing several phyto bioactives in different stages of preclinical studies with evidenced POC.
OUX - Proven antimicrobial effect against E.coli, addresses the bacterial presence, antibiotic resistance and biofilm, as well as symptoms and pathology in LUTIs and Interstitial Cystitis (IC). Additionally, based on case studies, when taken as directed, it exerts a protective effect on the bladder, helping prevent the onset of UTI. Real World Data in women ages 26-94.
Due to antimicrobial resistance UTIs have become a serious global health concern leading to an increase in hospitalization and sepsis cases.
UK Patent granted.
US Patent granted.
Trademarks US, UK & Japan.
US Patent granted.
EP Patent granted.
Japan, Canada & Mexico PPH pending.
Background: 1 in 7 women will be diagnosed with breast cancer. For women carriers of defective BRAC1/2 genes, women with dense breast tissue, women with a family history or women getting HRT proven to increase breast density, the risk is much higher, approximately 50%.
Breast Cancer Therapeutics Market size: USD 28.8 billion in 2022 projected to reach USD 73.68 billion by 2032 with a compound annual growth rate (CAGR) of 9.9%.
Demonstrated in-vitro inhibitory effect on the aggressive androgen independent type of prostate cancer cell. Case study demonstrating significant improvement in prostate health, sperm quality and maintaining prostate size with consistent use.
EP Patent granted.
US & Japan pending.
Background: Prostate health is crucial to men's health and wellbeing at all ages. 1 in 6 Caucasian men will be diagnosed with prostate cancer, while the risk in men of African descent is 1 in 4.
According to the American Urology Association:
- 90% of men between 45-80 suffer from some type of lower Urinary Tract Symptoms (LUTS).
- About half of all men between 51-60 have Benign Prostate Hyperplasia (BPH).
- Up to 90% of men over age 80 have BPH.
Lancet Commission on Prostate Cancer (April 2024): Prostate Cancer cases expected to double from 1.4million 2020 to 2.9 million by 2040- main increase in East Asia.